Targeted Proteomics to Identify Early Diagnostic Biomarkers for Anthracycline-Induced Cardiomyopathy in Long-Term Survivors of Childhood Cancer

Abstract

Introduction Plasma biomarkers may aid in the early diagnosis of anthracycline-induced cardiomyopathy in long-term childhood cancer survivors (CCS) and may provide insights into the underlying mechanisms involved. Natriuretic peptides and troponins are of limited value to diagnose left ventricular dysfunction in CCS >1 year after anthracycline treatment. To improve cardiomyopathy surveillance in long-term CCS, we aim to identify new plasma biomarkers for the early diagnosis of anthracycline-induced cardiomyopathy. Methods Five-year CCS treated with anthracyclines and ≥18 years at time of the study were identified from the ongoing Dutch Childhood Oncology Late Effects After Childhood Cancer (DCOG-LATER) study. Genetic cardiomyopathy cases were identified from a dilated cardiomyopathy cohort in the Amsterdam UMC (figure 1). Levels of 184 plasma proteins (from 32 different biological processes) were compared between three groups of 30 patients: anthracycline-induced cardiomyopathy cases (left ventricular ejection fraction (LVEF) Results The results will be available in August 2019 and will be presented during the congress. Conclusion Targeted proteomics in CCS treated with anthracyclines may identify new biomarkers for the early diagnosis of anthracycline-induced cardiomyopathy in CCS and may provide additional insights into the pathophysiology of anthracycline cardiomyopathy.